Cargando…

In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients

BACKGROUND: In osteosarcoma (OS) and most Ewing sarcoma (EWS) patients, the primary tumor originates in the bone. Although tumor resection surgery is commonly used to treat these diseases, it frequently leaves massive bone defects that are particularly difficult to be treated. Due to the therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucarelli, Enrico, Bellotti, Chiara, Mantelli, Melissa, Avanzini, Maria Antonietta, Maccario, Rita, Novara, Francesca, Arrigo, Giulia, Zuffardi, Orsetta, Zuntini, Monia, Pandolfi, Martina, Sangiorgi, Luca, Lisini, Daniela, Donati, Davide, Duchi, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022272/
https://www.ncbi.nlm.nih.gov/pubmed/24716831
http://dx.doi.org/10.1186/1479-5876-12-95
_version_ 1782316374815670272
author Lucarelli, Enrico
Bellotti, Chiara
Mantelli, Melissa
Avanzini, Maria Antonietta
Maccario, Rita
Novara, Francesca
Arrigo, Giulia
Zuffardi, Orsetta
Zuntini, Monia
Pandolfi, Martina
Sangiorgi, Luca
Lisini, Daniela
Donati, Davide
Duchi, Serena
author_facet Lucarelli, Enrico
Bellotti, Chiara
Mantelli, Melissa
Avanzini, Maria Antonietta
Maccario, Rita
Novara, Francesca
Arrigo, Giulia
Zuffardi, Orsetta
Zuntini, Monia
Pandolfi, Martina
Sangiorgi, Luca
Lisini, Daniela
Donati, Davide
Duchi, Serena
author_sort Lucarelli, Enrico
collection PubMed
description BACKGROUND: In osteosarcoma (OS) and most Ewing sarcoma (EWS) patients, the primary tumor originates in the bone. Although tumor resection surgery is commonly used to treat these diseases, it frequently leaves massive bone defects that are particularly difficult to be treated. Due to the therapeutic potential of mesenchymal stem cells (MSCs), OS and EWS patients could benefit from an autologous MSCs-based bone reconstruction. However, safety concerns regarding the in vitro expansion of bone marrow-derived MSCs have been raised. To investigate the possible oncogenic potential of MSCs from OS or EWS patients (MSC-SAR) after expansion, this study focused on a biosafety assessment of MSC-SAR obtained after short- and long-term cultivation compared with MSCs from healthy donors (MSC-CTRL). METHODS: We initially characterized the morphology, immunophenotype, and differentiation multipotency of isolated MSC-SAR. MSC-SAR and MSC-CTRL were subsequently expanded under identical culture conditions. Cells at the early (P3/P4) and late (P10) passages were collected for the in vitro analyses including: sequencing of genes frequently mutated in OS and EWS, evaluation of telomerase activity, assessment of the gene expression profile and activity of major cancer pathways, cytogenetic analysis on synchronous MSCs, and molecular karyotyping using a comparative genomic hybridization (CGH) array. RESULTS: MSC-SAR displayed comparable morphology, immunophenotype, proliferation rate, differentiation potential, and telomerase activity to MSC-CTRL. Both cell types displayed signs of senescence in the late stages of culture with no relevant changes in cancer gene expression. However, cytogenetic analysis detected chromosomal anomalies in the early and late stages of MSC-SAR and MSC-CTRL after culture. CONCLUSIONS: Our results demonstrated that the in vitro expansion of MSCs does not influence or favor malignant transformation since MSC-SAR were not more prone than MSC-CTRL to deleterious changes during culture. However, the presence of chromosomal aberrations supports rigorous phenotypic, functional and genetic evaluation of the biosafety of MSCs, which is important for clinical applications.
format Online
Article
Text
id pubmed-4022272
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40222722014-05-16 In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients Lucarelli, Enrico Bellotti, Chiara Mantelli, Melissa Avanzini, Maria Antonietta Maccario, Rita Novara, Francesca Arrigo, Giulia Zuffardi, Orsetta Zuntini, Monia Pandolfi, Martina Sangiorgi, Luca Lisini, Daniela Donati, Davide Duchi, Serena J Transl Med Research BACKGROUND: In osteosarcoma (OS) and most Ewing sarcoma (EWS) patients, the primary tumor originates in the bone. Although tumor resection surgery is commonly used to treat these diseases, it frequently leaves massive bone defects that are particularly difficult to be treated. Due to the therapeutic potential of mesenchymal stem cells (MSCs), OS and EWS patients could benefit from an autologous MSCs-based bone reconstruction. However, safety concerns regarding the in vitro expansion of bone marrow-derived MSCs have been raised. To investigate the possible oncogenic potential of MSCs from OS or EWS patients (MSC-SAR) after expansion, this study focused on a biosafety assessment of MSC-SAR obtained after short- and long-term cultivation compared with MSCs from healthy donors (MSC-CTRL). METHODS: We initially characterized the morphology, immunophenotype, and differentiation multipotency of isolated MSC-SAR. MSC-SAR and MSC-CTRL were subsequently expanded under identical culture conditions. Cells at the early (P3/P4) and late (P10) passages were collected for the in vitro analyses including: sequencing of genes frequently mutated in OS and EWS, evaluation of telomerase activity, assessment of the gene expression profile and activity of major cancer pathways, cytogenetic analysis on synchronous MSCs, and molecular karyotyping using a comparative genomic hybridization (CGH) array. RESULTS: MSC-SAR displayed comparable morphology, immunophenotype, proliferation rate, differentiation potential, and telomerase activity to MSC-CTRL. Both cell types displayed signs of senescence in the late stages of culture with no relevant changes in cancer gene expression. However, cytogenetic analysis detected chromosomal anomalies in the early and late stages of MSC-SAR and MSC-CTRL after culture. CONCLUSIONS: Our results demonstrated that the in vitro expansion of MSCs does not influence or favor malignant transformation since MSC-SAR were not more prone than MSC-CTRL to deleterious changes during culture. However, the presence of chromosomal aberrations supports rigorous phenotypic, functional and genetic evaluation of the biosafety of MSCs, which is important for clinical applications. BioMed Central 2014-04-09 /pmc/articles/PMC4022272/ /pubmed/24716831 http://dx.doi.org/10.1186/1479-5876-12-95 Text en Copyright © 2014 Lucarelli et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lucarelli, Enrico
Bellotti, Chiara
Mantelli, Melissa
Avanzini, Maria Antonietta
Maccario, Rita
Novara, Francesca
Arrigo, Giulia
Zuffardi, Orsetta
Zuntini, Monia
Pandolfi, Martina
Sangiorgi, Luca
Lisini, Daniela
Donati, Davide
Duchi, Serena
In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients
title In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients
title_full In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients
title_fullStr In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients
title_full_unstemmed In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients
title_short In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients
title_sort in vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022272/
https://www.ncbi.nlm.nih.gov/pubmed/24716831
http://dx.doi.org/10.1186/1479-5876-12-95
work_keys_str_mv AT lucarellienrico invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT bellottichiara invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT mantellimelissa invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT avanzinimariaantonietta invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT maccariorita invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT novarafrancesca invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT arrigogiulia invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT zuffardiorsetta invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT zuntinimonia invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT pandolfimartina invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT sangiorgiluca invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT lisinidaniela invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT donatidavide invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients
AT duchiserena invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients